Oct 14
Episode 167: Pancreatic Cancer Series, Pt. 2 – Resectable Disease
This week our pancreatic cancer series moves from diagnosis to management, starting with resectable disease. Using the case of a 68-year-old man with a 2.8 cm adenocarcinoma of the pancreatic head, we define what "resectable" actually means, review the operation and the goal of a ... Show More
26m 23s
Oct 7
Episode 166: Pancreatic Cancer Series, Pt. 1 – Biology, Diagnosis, and Staging
This week we kick off a brand-new series on pancreatic cancer, starting with the fundamentals. Using the case of a 68-year-old man with painless jaundice, weight loss, and new-onset diabetes, we cover the epidemiology and sobering survival statistics of pancreatic ductal adenocar ... Show More
28m 52s
Sep 23
Episode 165: CLL Updates Series, Pt. 2 – Relapsed/Refractory in 2026
This week we wrap up our two-part CLL update by turning to relapsed and refractory disease. We pick up with the 68-year-old man from Part 1, now a year out from frontline therapy and showing signs of relapse. We cover when relapse actually needs treatment, the history of BTK inhi ... Show More
22m 22s
May 2022
Acute Myeloid Leukemia (AML)
<p>Today’s episode is all about AML (acute myeloid leukemia), including the usual presentation, diagnostic work-up, risk stratification (and tricks to remember these), molecular testing, and treatment options for first-line, as well as relapsed/refractory disease.</p>
15m 18s
Aug 2021
Latest Research on the Intensity of AML Therapy in Older Patients, Platelets and T cell Activity in Sepsis, and Genotyping for CNS Lymphoma
In this week's episode, we’ll start by reviewing an intriguing study that, while not randomized, calls into question whether less-intensive induction therapies provide a survival or quality of life benefit in older patients with AML. Next, we will review the somewhat surprising f ... Show More
19m 21s
May 2022
S1 Episode 2: Frontline Therapy for Multiple Myeloma
Joseph Mikhael, MD, and Peter Voorhees, MD, discuss frontline therapy for multiple myeloma and new options for both transplant-eligible and transplant-ineligible patients. Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/view ... Show More
23m 37s
Nov 2021
Machine learning in classification of AML, aging bone marrow in leukemia, and treating bleeding disorders of unknown cause
In this week’s episode, we’ll learn more about the application of machine learning in molecular subclassification and prognostication of acute myeloid leukemia or AML, discuss the role of aging bone marrow in leukemia progression, and learn more about the challenges in treating b ... Show More
19m 25s
May 2025
Measurable residual disease and maintenance therapy in acute myeloid leukemia (AML), stemness and chemotherapy resistance in AML, and effects of babesiosis on red blood cells in sickle cell disease
In this week's episode, we’ll learn more about how measurable residual disease might help guide decisions about post-transplant gilteritinib maintenance in FLT3-ITD acute myeloid leukemia, or AML; how stemness contributes to chemotherapy resistance in AML; and effects of babesios ... Show More
19m 58s
Sep 2025
S2 Episode 3: When Is the Best Time to Use CAR T-Cell Therapy in Multiple Myeloma?
Joseph Mikhael, MD, and Krina K. Patel, MD, MSc, discuss considerations for CAR T-Cell therapy in multiple myeloma, including age, access, and bridging therapy. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002715. ... Show More
24m 38s
In today’s episode, we discuss how to approach AML treatment for patients who are unfit for intensive therapy.
Episode contents:
- How do we assess fitness for intensive AML?
- What are options for patients who are unfit for intensive chemotherapy for AML?
- What are important genetic mutations are important to check for?
- What are the key trials that inf ... Show More
